Depletion of MGMT, using the artificial substrate O6-benzylguanine, has been shown to sensitise tumour cells to alkylating chemotherapy.24 We thus, hypothesised that BTZ pre-treatment may sensitise chemoresistant GBM cells to TMZ. The gene discussed is CASC3; the disease is neoplasm.